LTRN
Lantern Pharma Inc
NASDAQ: LTRN · HEALTHCARE · BIOTECHNOLOGY
$2.05
+3.54% today
Updated 2026-04-30
Market cap
$27.69M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.57
Dividend yield
—
52W range
$1 – $6
Volume
0.7M
Lantern Pharma Inc (LTRN) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-1.27M | $-2.13M | $-5.65M | $-10.59M | $-12.77M | $-14.35M | $-17.81M | $-15.68B |
| Capital expenditures | $5717.00 | $5717.00 | $16137.00 | $15499.00 | $27844.00 | $18734.00 | $12599.00 | $1715.00 |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | $185604.00 | $117760.00 | $1.19M | $961545.00 | $1.19M | $1.07M | $732893.00 | $650877.00 |
| Free cash flow | $-1.28M | $-2.13M | $-5.67M | $-10.61M | $-12.80M | $-14.37M | $-17.83M | $-15.68B |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $18.00M | — | $-14.77M | — | — | — |